Literature DB >> 10335932

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS).

P J Hollen1, R J Gralla, M G Kris, S W Eberly, C Cox.   

Abstract

Normative data and trends for a disease- and site-specific quality of life (QL) instrument for individuals with lung cancer, the Lung Cancer Symptom Scale (LCSS), are presented to facilitate the user's interpretation of test scores. Data for patients enrolled in two large, identical, randomized trials of a new combination chemotherapy regimen for patients with stages III and IV non-small-cell lung cancer (NSCLC) were combined into one dataset (n = 673). For these patients with a Karnofsky performance status (KPS) of 60-100%, QL had been prospectively measured at baseline, day 29 and every 6 weeks thereafter. Descriptive statistics for the LCSS are presented for three time points (baseline, day 29 and day 71) and for specific demographic and disease-related characteristics (age, gender, race, performance status and stage of disease) to provide expected values and their variability during chemotherapy. Data from a small dataset of 63 NSCLC inpatients with KPS scores of 20-50% are also presented for a comparison sample of supportive care for inpatients and hospice patients. For the 673 NSCLC patients at baseline there were no significant differences in QL by age, gender, or race. Major presenting lung cancer symptoms at baseline for this combined sample were dyspnea 87%, cough 86%, pain 81%, loss of appetite 75%, and hemoptysis 41%. Of these patients, 81% had three or more presenting symptoms at baseline (2% had no symptoms; 5%, one symptom; 12%, two symptoms; 18%, three symptoms; 27%, four symptoms; and 36%, five symptoms). The mean LCSS baseline score (best = 0; worst = 100) was 26.56 (SD 16.10). The mean scores for day 29 and day 71 were 25.46 (SD 16.52) and 25.30 (SD 16.93), respectively, but follow-up assessments on progressers were not obtained. Stage III patients had a mean LCSS score of 23.7 (SD 15.1), whereas stage IV patients reported a mean LCSS score of 27.3 (SD 16.3). The mean LCSS score for the group with KPS 60-70% was 34.8 (SD 15.5), and that for the group with KPS 80-100% was 23.3 (SD 15.1). The mean LCSS score for the lower performance group, with KPS scores of 20-50% at baseline, was 46.85 (SD 17.65).

Entities:  

Mesh:

Year:  1999        PMID: 10335932     DOI: 10.1007/s005200050244

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  25 in total

1.  Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial.

Authors:  Terence T Sio; Pamela J Atherton; Levi D Pederson; W Ken Zhen; Robert W Mutter; Yolanda I Garces; Daniel J Ma; James L Leenstra; Jean-Claude M Rwigema; Shaker Dakhil; James D Bearden; Sonja J van der Veen; Apar K Ganti; Steven E Schild; Robert C Miller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-02       Impact factor: 7.038

Review 2.  The clinical significance of quality of life assessments in oncology: a summary for clinicians.

Authors:  Jeff A Sloan; Marlene H Frost; Rick Berzon; Amylou Dueck; Gordon Guyatt; Carol Moinpour; Mirjam Sprangers; Carol Ferrans; David Cella
Journal:  Support Care Cancer       Date:  2006-06-23       Impact factor: 3.603

Review 3.  A systematic review of measures of end-of-life care and its outcomes.

Authors:  Richard A Mularski; Sydney M Dy; Lisa R Shugarman; Anne M Wilkinson; Joanne Lynn; Paul G Shekelle; Sally C Morton; Virginia C Sun; Ronda G Hughes; Lara K Hilton; Margaret Maglione; Shannon L Rhodes; Cony Rolon; Karl A Lorenz
Journal:  Health Serv Res       Date:  2007-10       Impact factor: 3.402

4.  Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.

Authors:  Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

5.  Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics.

Authors:  S Trippoli; M Vaiani; C Lucioni; A Messori
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Quality of life and symptom burden among long-term lung cancer survivors.

Authors:  Ping Yang; Andrea L Cheville; Jason A Wampfler; Yolanda I Garces; Aminah Jatoi; Matthew M Clark; Stephen D Cassivi; David E Midthun; Randolph S Marks; Marie-Christine Aubry; Scott H Okuno; Brent A Williams; Francis C Nichols; Victor F Trastek; Hiroshi Sugimura; Linda Sarna; Mark S Allen; Claude Deschamps; Jeff A Sloan
Journal:  J Thorac Oncol       Date:  2012-01       Impact factor: 15.609

7.  Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL).

Authors:  Patricia J Hollen; Richard J Gralla; John A Stewart; Jacinta M Meharchand; Rafal Wierzbicki; Natasha Leighl
Journal:  Support Care Cancer       Date:  2012-06-10       Impact factor: 3.603

8.  A psychometric analysis of quality of life tools in lung cancer patients who smoke.

Authors:  Kristine K Browning; Amy K Ferketich; Gregory A Otterson; Nancy R Reynolds; Mary Ellen Wewers
Journal:  Lung Cancer       Date:  2009-01-31       Impact factor: 5.705

9.  Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.

Authors:  Patricia J Hollen; Richard J Gralla; Ryan D Gentzler; Richard D Hall; Bethany Coyne; Haiying Cheng; Balazs Halmos; Jane Gildersleeve; Claudia Calderon; Ivora Hinton; Geoffrey Weiss; Jeffrey Crawford; Jane Cerise; Martin Lesser
Journal:  Oncologist       Date:  2020-11-10

10.  Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.

Authors:  Patricia J Hollen; Richard J Gralla; Cynthia N Rittenberg
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.